drugset
drugset / Trial / NCT07464327

A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations

NCT07464327 ↗

Phase 3 Not yet recruiting 450 enrolled Hansoh BioMedical R&D Company
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a multicenter, randomized, open-label, controlled phase III clinical study to evaluate the efficacy and safety of HS-20093 injection combined with adebrelimab versus docetaxel in previously treated patients with advanced or metastatic non-squamous non-small cell lung cancer without actionable genomic alterations.

Timeline

Start
2026-03-31
Primary completion
2028-12-31
Completion
2029-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Adebrelimab Monoclonal antibody 1200 mg Intravenous
Comparator Docetaxel Small molecule 75 mg/m2 —
Subject HS-20093 Other / unclassified 8 mg/kg Intravenous

Indications

non-small cell lung carcinoma